

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease

<https://marketpublishers.com/r/C6A11E00BF2EN.html>

Date: January 2015

Pages: 32

Price: US\$ 260.00 (Single User License)

ID: C6A11E00BF2EN

Abstracts

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease

The Competitive Intelligence report about **Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease** provides a competitor analysis in the discovery and development pipeline of novel therapeutics for treatment of Parkinson's Disease (PD). Alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) represent molecular targets for novel drug candidates to treat PD. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Of the various genetic factors contributing to the pathogenesis of Parkinson's disease, only mutations in alpha-synuclein and LRRK2 genes cause clinical and neuropathological phenotypes closely resembling the sporadic cases. Therefore, studying the pathophysiological functions of these two PD-related genes is particularly informative in understanding the underlying molecular pathogenic mechanism of the disease. PD-related missense and multiplication mutations in α -synuclein may cause both early- and late-onset PD, whereas various PD-related LRRK2 missense mutations may contribute to the more common late-onset PD.

The report provides a compilation of active projects in research and development for treatment of Parkinson's disease based on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed in a tabular format providing information on:

Drug Codes

Target / Mechanism of Action

Class of Compound

Company

Product Category

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

Alpha Synuclein Inhibitors

LRRK2 Inhibitors

Corporate R&D Pipelines of alpha Synuclein and LRRK2 Inhibitors

I would like to order

Product name: Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease

Product link: <https://marketpublishers.com/r/C6A11E00BF2EN.html>

Price: US\$ 260.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6A11E00BF2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

